Standout Papers

Cardiovasc... 1975 2026 1992 2009 962
  1. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes (2020)
    Christopher P. Cannon, Richard E. Pratley et al. New England Journal of Medicine
  2. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes (2020)
    Darren K. McGuire, Weichung Shih et al. JAMA Cardiology
  3. Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone (2006)
    B Charbonnel, Avraham Karasik et al. Diabetes Care
  4. Radioimmunoassay of Prostaglandins Fα, E1 and E2 in Human Plasma (1975)
    F. Dray, B Charbonnel et al. European Journal of Clinical Investigation

Immediate Impact

5 by Nobel laureates 4 from Science/Nature 78 standout
Sub-graph 1 of 16

Citing Papers

Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
2025 Standout
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
2023 Standout
6 intermediate papers

Works of B Charbonnel being referenced

Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes
2020 Standout
Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone
2006 Standout
and 3 more

Author Peers

Author Last Decade Papers Cites
B Charbonnel 6864 3248 2763 236 9.4k
Russell Scott 5727 2616 4665 237 11.1k
Guntram Schernthaner 6064 2851 2636 223 10.6k
Boaz Hirshberg 6032 2656 3478 118 8.5k
Jorge Luiz Gross 5592 2270 2183 235 10.2k
Lawrence Blonde 8000 3280 2827 182 10.0k
Eberhard Standl 5815 2049 2322 205 8.8k
Zachary T. Bloomgarden 5684 2040 2185 263 9.1k
William C. Duckworth 7076 3740 2931 198 12.7k
Vanita R. Aroda 6780 3070 2002 164 9.5k
Paola Fioretto 3942 1817 1981 191 9.8k

All Works

Loading papers...

Rankless by CCL
2026